Skip to main content
Erschienen in: Pediatric Cardiology 8/2023

25.08.2023 | Research

QRS Duration After Pulmonary Valve Replacement in Adults with Repaired Tetralogy of Fallot: Association with Ventricular Arrhythmia and Correlation with Right Ventricular Size

verfasst von: Rody G. Bou Chaaya, Emily Barron, Jeremy L. Herrmann, John W. Brown, Georges Ephrem

Erschienen in: Pediatric Cardiology | Ausgabe 8/2023

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to analyze the relationship between QRS duration after pulmonary valve replacement (PVR) and ventricular arrhythmias (VA) in patients with repaired tetralogy of Fallot (ToF). ToF patients may face complications such as heart failure and VA after primary repair, often mitigated by PVR. Prior studies have shown a decrease in QRS duration and right ventricular (RV) size following PVR. It remains unclear whether a lack of QRS duration reduction identifies patients at risk of VA. We retrospectively identified adult patients with repaired ToF who underwent surgical or transcatheter PVR. EKG data (pre-PVR, 30 days to 1-year post-PVR, and closest to CMR) was collected. The primary endpoint was sustained ventricular tachycardia (VT), ICD shock for sustained VT, or inducible VT on EP study. 85 patients were included (median follow-up 3.6 years; median age 34 years; 51% females). The primary outcome was noted in 8 patients. Mean QRS duration decreased by 5 ms following PVR (p = 0.0001). Increased age at PVR, QRS ≥ 180 ms post-PVR, no reduction in QRS after PVR, and a history of VT were associated with higher risk of the primary endpoint. The change in QRS was linearly correlated with the change in RVEDVi (R = 0.66). Adults with repaired ToF experience a reduction in QRS duration post-PVR that correlates with the change of the RV size. Patients with QRS ≥ 180 ms post-PVR, no reduction in QRS, increased age at repair, and a history of VT are at risk for recurrent VT and warrant closer monitoring/ICD consideration.
Literatur
1.
Zurück zum Zitat Bokma JP, Winter MM, Oosterhof T et al (2016) Pulmonary valve replacement after repair of pulmonary stenosis compared with tetralogy of Fallot. J Am Coll Cardiol 67(9):1123–1124CrossRefPubMed Bokma JP, Winter MM, Oosterhof T et al (2016) Pulmonary valve replacement after repair of pulmonary stenosis compared with tetralogy of Fallot. J Am Coll Cardiol 67(9):1123–1124CrossRefPubMed
2.
Zurück zum Zitat Warnes CA, Williams RG, Bashore TM et al (2008) ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). Circulation 118(23):2395–2451CrossRefPubMed Warnes CA, Williams RG, Bashore TM et al (2008) ACC/AHA 2008 guidelines for the management of adults with congenital heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to develop guidelines for the management of adults with congenital heart disease). Circulation 118(23):2395–2451CrossRefPubMed
3.
Zurück zum Zitat Gatzoulis MA, Balaji S, Webber SA et al (2000) Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 356(9234):975–981CrossRefPubMed Gatzoulis MA, Balaji S, Webber SA et al (2000) Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 356(9234):975–981CrossRefPubMed
4.
Zurück zum Zitat Aleligne Y, Eyvazian VA, Reardon L et al (2019) The effects of pulmonary valve replacement on QRS duration in repaired tetralogy of Fallot patients with pulmonary regurgitation. J Electrocardiol 54:36–39CrossRefPubMed Aleligne Y, Eyvazian VA, Reardon L et al (2019) The effects of pulmonary valve replacement on QRS duration in repaired tetralogy of Fallot patients with pulmonary regurgitation. J Electrocardiol 54:36–39CrossRefPubMed
5.
Zurück zum Zitat Van Huysduynen BH, van Straten A, Swenne CA et al (2005) Reduction of QRS duration after pulmonary valve replacement in adult fallot patients is related to reduction of right ventricular volume. Eur Heart J 26(9):928–932CrossRefPubMed Van Huysduynen BH, van Straten A, Swenne CA et al (2005) Reduction of QRS duration after pulmonary valve replacement in adult fallot patients is related to reduction of right ventricular volume. Eur Heart J 26(9):928–932CrossRefPubMed
6.
Zurück zum Zitat Scherptong RW, Hazekamp MG, Mulder BJ et al (2010) Follow-up after pulmonary valve replacement in adults with tetralogy of Fallot: association between QRS duration and outcome. J Am Coll Cardiol 56:1486–1492CrossRefPubMed Scherptong RW, Hazekamp MG, Mulder BJ et al (2010) Follow-up after pulmonary valve replacement in adults with tetralogy of Fallot: association between QRS duration and outcome. J Am Coll Cardiol 56:1486–1492CrossRefPubMed
7.
Zurück zum Zitat Therrien J, Siu SC, Harris L et al (2001) Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 103:2489–2494CrossRefPubMed Therrien J, Siu SC, Harris L et al (2001) Impact of pulmonary valve replacement on arrhythmia propensity late after repair of tetralogy of Fallot. Circulation 103:2489–2494CrossRefPubMed
8.
Zurück zum Zitat Baumgartner H, De Backer J, Babu-Narayan SV et al (2021) ESC scientific document group. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J 42(6):563–645CrossRefPubMed Baumgartner H, De Backer J, Babu-Narayan SV et al (2021) ESC scientific document group. 2020 ESC guidelines for the management of adult congenital heart disease. Eur Heart J 42(6):563–645CrossRefPubMed
9.
Zurück zum Zitat Oosterhof T, Vliegen HW, Meijboom FJ et al (2007) Long-term effect of pulmonary valve replacement on QRS duration in patients with corrected tetralogy of Fallot. Heart 93(4):506–509CrossRefPubMed Oosterhof T, Vliegen HW, Meijboom FJ et al (2007) Long-term effect of pulmonary valve replacement on QRS duration in patients with corrected tetralogy of Fallot. Heart 93(4):506–509CrossRefPubMed
10.
Zurück zum Zitat Babu-Narayan SV, Kilner PJ, Li W et al (2006) Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation 113(3):405–413CrossRefPubMed Babu-Narayan SV, Kilner PJ, Li W et al (2006) Ventricular fibrosis suggested by cardiovascular magnetic resonance in adults with repaired tetralogy of Fallot and its relationship to adverse markers of clinical outcome. Circulation 113(3):405–413CrossRefPubMed
11.
Zurück zum Zitat Bokma JP, Winter MM, Vehmeijer JT et al (2017) QRS fragmentation is superior to QRS duration in predicting mortality in adults with tetralogy of Fallot. Heart 103(9):666–671CrossRefPubMed Bokma JP, Winter MM, Vehmeijer JT et al (2017) QRS fragmentation is superior to QRS duration in predicting mortality in adults with tetralogy of Fallot. Heart 103(9):666–671CrossRefPubMed
12.
Zurück zum Zitat Waldmann V, Bouzeman A, Duthoit G et al (2020) Long-term follow-up of patients with tetralogy of Fallot and implantable cardioverter defibrillator: the DAI-T4F nationwide registry. Circulation 142(17):1612–1622CrossRefPubMed Waldmann V, Bouzeman A, Duthoit G et al (2020) Long-term follow-up of patients with tetralogy of Fallot and implantable cardioverter defibrillator: the DAI-T4F nationwide registry. Circulation 142(17):1612–1622CrossRefPubMed
13.
Zurück zum Zitat Sabate Rotes A, Connolly HM, Warnes CA et al (2015) Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 8(1):110–116CrossRefPubMed Sabate Rotes A, Connolly HM, Warnes CA et al (2015) Ventricular arrhythmia risk stratification in patients with tetralogy of Fallot at the time of pulmonary valve replacement. Circ Arrhythm Electrophysiol 8(1):110–116CrossRefPubMed
14.
Zurück zum Zitat Book WM, Parks WJ, Hopkins KL et al (1999) Electrocardiographic predictors of right ventricular volume measured by magnetic resonance imaging late after total repair of tetralogy of Fallot. Clin Cardiol 22:740–746CrossRefPubMed Book WM, Parks WJ, Hopkins KL et al (1999) Electrocardiographic predictors of right ventricular volume measured by magnetic resonance imaging late after total repair of tetralogy of Fallot. Clin Cardiol 22:740–746CrossRefPubMed
Metadaten
Titel
QRS Duration After Pulmonary Valve Replacement in Adults with Repaired Tetralogy of Fallot: Association with Ventricular Arrhythmia and Correlation with Right Ventricular Size
verfasst von
Rody G. Bou Chaaya
Emily Barron
Jeremy L. Herrmann
John W. Brown
Georges Ephrem
Publikationsdatum
25.08.2023
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 8/2023
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-023-03272-0

Weitere Artikel der Ausgabe 8/2023

Pediatric Cardiology 8/2023 Zur Ausgabe

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.